Yhun Yhong Sheen Selected Research

Therapeutics

1/2022	Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor.
11/2015	Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
5/2015	EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.
7/2014	EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
9/2013	Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy.
5/2012	Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yhun Yhong Sheen Research Topics

Disease

14	Neoplasms (Cancer) 01/2022 - 11/2003
12	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2004
6	Neoplasm Metastasis (Metastasis) 11/2015 - 10/2011
4	Fibrosis (Cirrhosis) 01/2022 - 08/2014
2	Lymphoma (Lymphomas) 03/2012 - 02/2012
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 01/2022
1	Leukemia 02/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 05/2015
1	Ureteral Obstruction 05/2015
1	Hypoxia (Hypoxemia) 06/2013
1	Carcinogenesis 07/2010
1	Carcinoma (Carcinomatosis) 07/2010
1	Hepatocellular Carcinoma (Hepatoma) 04/2004
1	Neuroblastoma 11/2003

Drug/Important Bio-Agent (IBA)

7	Phosphotransferases (Kinase)IBA 01/2016 - 10/2011
5	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 09/2013
5	vactosertibIBA 01/2022 - 07/2014
5	Histone Deacetylase InhibitorsIBA 05/2012 - 05/2004
4	Estrogen ReceptorsIBA 05/2012 - 05/2004
3	3- (4- dimethylaminophenyl)- N- hydroxy- 2- propenamideIBA 05/2012 - 01/2012
3	CarcinogensIBA 03/2012 - 07/2010
2	ProteomeIBA 03/2012 - 02/2012
2	Biomarkers (Surrogate Marker)IBA 03/2012 - 02/2012
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2012 - 01/2012
2	benzonitrileIBA 11/2011 - 10/2011
2	trichostatin A (A 300)IBA 06/2004 - 05/2004
2	HC toxinIBA 06/2004 - 05/2004
1	Fibronectins (Fibronectin)IBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 02/2016
1	Therapeutic UsesIBA 11/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2015
1	Carbon Tetrachloride (Tetrachloromethane)IBA 05/2015
1	Bleomycin (Blenoxane)FDA LinkGeneric 05/2015
1	3- ((5- (6- methylpyridin- 2- yl)- 4- (quinoxalin- 6- yl)- 1H- imidazol- 2- yl)methyl)benzamideIBA 08/2014
1	Aldehyde DehydrogenaseIBA 06/2013
1	C.I. Solvent Yellow 56 (DEAB)IBA 06/2013
1	Estrogen Receptor Modulators (Antiestrogen)IBA 05/2012
1	Ethylene Dibromide (1,2 Dibromoethane)IBA 03/2012
1	2-nitrotolueneIBA 03/2012
1	Emodin (Archin)IBA 03/2012
1	Mannitol (Osmitrol)FDA LinkGeneric 03/2012
1	moesinIBA 02/2012
1	CyclinsIBA 01/2012
1	Hormones (Hormone)IBA 01/2012
1	Apoptosis Regulatory ProteinsIBA 01/2012
1	EnzymesIBA 01/2012
1	Thymidylate SynthaseIBA 01/2012
1	3- ((4- ((1,2,4)triazolo(1,5- a)pyridin- 6- yl)- 5- (6- methylpyridin- 2- yl)- 1H- imidazol- 2- yl)methylamino)benzonitrileIBA 11/2011
1	Activin Receptors (Activin Receptor)IBA 10/2011
1	3- ((5- ((1,2,4)triazolo(1,5- a)pyridin- 6- yl)- 4- (6- methylpyridin- 2- yl)thiazol- 2- ylamino)methyl)benzonitrileIBA 10/2011
1	Melphalan (Alkeran)FDA LinkGeneric 07/2010
1	Proteins (Proteins, Gene)FDA Link 07/2010
1	Oncogene Proteins (Oncogene Protein)IBA 07/2010
1	Caspase 3 (Caspase-3)IBA 06/2004
1	Cytochrome P-450 CYP3AIBA 04/2004
1	Histones (Histone)IBA 04/2004
1	PPAR gammaIBA 11/2003
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2003
1	LigandsIBA 11/2003

Therapy/Procedure

6	Therapeutics 01/2022 - 05/2012
2	Ligation 01/2016 - 05/2015
1	Radiotherapy 01/2022
1	Drug Therapy (Chemotherapy) 11/2015